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Psoriatic arthritis
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ABSTRACT

Objectives We examined patient-reported outcomes
(PROs) in The Study of Etanercept And Methotrexate in
Patients with Psoriatic Arthritis (PsA); a 48-week, phase
3, randomised controlled trial that compared outcomes
with methotrexate (MTX) monotherapy, etanercept
monotherapy, and MTX+ etanercept in patients with PsA.
Methods Efficacy endpoints included: mean changes
from baseline and proportion of patients who reported
improvements≥minimal clinically important difference
(MCID) at week 24 in treatment groups for Health
Assessment Questionnaire-Disability Index, Patient Global
Assessment (PtGA), Patient Global Assessment of Joint
Pain (PtGAJP) and Medical Outcomes Study Short Form36 Questionnaire (SF-36) Physical Component Summary
(PCS), and Mental Component Summary, and eight domain
scores. PROs were analysed as reported (observed),
without multiplicity adjustment; therefore, p values are
descriptive.
Results At week 24, patients receiving etanercept
monotherapy or MTX+ etanercept combination reported
greater improvements (p≤0.05) in PtGA, PtGAJP and
SF-36 PCS scores compared with those receiving MTX
monotherapy. Compared with MTX monotherapy, higher
proportions of patients receiving etanercept monotherapy
and combination therapy reported improvements≥MCID
in PtGA (etanercept vs MTX, p=0.005) and PtGAJP (MTX
+etanercept vs MTX, p=0.038). Across PROs, proportions
of patients reporting scores≥age and gender-matched
normative values at week 24 ranged from 20.8% to 51.0%
with MTX monotherapy, 30.9% to 48.8% with etanercept
monotherapy, and 30.6% to 52.3% with MTX+ etanercept
combination.
Conclusions Patients receiving etanercept monotherapy
or MTX+ etanercept reported greater improvements from
baseline in several PROs compared with those receiving
MTX monotherapy. PROs should be incorporated in
discussions between patients and clinicians regarding
their treatment choices as they can help determine
which treatments are more beneficial in patients with
PsA.

Key messages
What is already known about this subject?
►► Patients with psoriatic arthritis (PsA) have lower

health-related quality of life compared with the general population, as measured by patient-reported
outcomes (PROs). PROs can improve with commonly used treatments for PsA, such as methotrexate
(MTX) and tumour necrosis factor inhibitors.
►► However, few studies exist that have directly compared the therapeutic effect of MTX with a tumour
necrosis factor inhibitor on PROs in patients with
PsA.

What does this study add?
►► This study analyzes PRO data captured in a phase

3, randomised controlled trial that directly compared
the effect of MTX monotherapy versus etanercept
(a tumour necrosis factor inhibitor) monotherapy
or MTX plus etanercept combination therapy in patients with PsA who were treatment naïve.
►► Etanercept monotherapy and combination therapy
were more effective than MTX monotherapy for improvement in PROs (and, in many cases, clinically
meaningful outcomes were reported) in patients
with PsA.

How might this impact on clinical practice?
►► Improvements in PROs with etanercept may inform

decision-
making between clinicians and patients
with PsA.

INTRODUCTION
Psoriatic arthritis (PsA) is a progressive,
chronic inflammatory disease with both joint
and skin-related manifestations. Patients with
PsA can experience a multitude of symptoms
including peripheral and axial joint inflammation, enthesis inflammation (enthesitis;
inflammation of the areas where tendons
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or ligaments attach to bones), finger or toe inflammation (dactylitis), nail disease and psoriasis.1 In patients
with psoriasis, about 30% develop PsA with an annual
incidence of 1%–3%.2–5 Effective disease management
requires not only timely diagnosis and treatment but
also recognition that PsA can adversely affect patient-
reported outcomes (PROs). Previous research suggests
that, in general, patients with PsA report worse PRO
scores compared with either the general population or
patients with psoriasis.6–9 PsA is associated with considerable disease burden including bodily pain and physical
function below that of age-matched and gender-matched
norms,10 fatigue, increased absenteeism from work,
and decreased work productivity.11–14 When assessing
the overall clinical value of PsA treatments, PRO measures should be included since health-related quality of
life (HRQoL), physical function and global assessments
are affected by treatment efficacy, safety, tolerability,
dosing frequency and route of administration. Disease-
modifying antirheumatic drugs (DMARDs) used to treat
PsA such as methotrexate (MTX) and tumour necrosis
factor inhibitors (TNFis) can improve PROs related to
physical ability, joint pain and mental ability in patients
with PsA.9 15 Although MTX, as a monotherapy or in a
combination regimen, is widely used to treat PsA, the
evidence supporting its use in this disease setting is
limited. Further, few randomised controlled trials (RCTs)
in PsA have examined PROs when directly comparing
MTX with a TNFi or in combination with a TNFi. These
include a study that compared MTX monotherapy versus
placebo in patients with psoriasis16 and a study that
compared MTX monotherapy versus golimumab and
MTX combination therapy in patients with early PsA.17
The Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic
Arthritis (SEAM-PsA)18 reported that both etanercept
monotherapy and combination therapy were statistically
significantly more effective than MTX monotherapy by
the percentage of patients who were American College
of Rheumatology 20% responders (ACR20, primary
endpoint) and had Minimal Disease Activity (MDA)
(key secondary endpoint) at week 24. Week-48 safety
outcomes indicated that no deaths occurred in the study
and that the incidences of adverse events and serious
adverse events were similar across the three treatment
groups.18 Published PRO results with the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the
Medical Outcomes Study Short Form-36 Questionnaire
(SF-36) showed similar improvements in HAQ-DI and
Mental Component Summary (MCS) scores from baseline to week 24 in all three treatment groups.18 However,
the SF-36 Physical Component Summary (PCS) score
showed greater mean changes from baseline at week
24 in both etanercept groups compared with MTX
monotherapy.
Here, we report additional PRO measures from the
SEAM-
PsA RCT examining the effect of MTX monotherapy, etanercept monotherapy, and MTX plus
2

etanercept combination therapy on PROs that evaluated HRQoL, physical function and global assessments
of disease activity, including: HAQ-
DI, Patient Global
Assessment of disease activity (PtGA), Patient Global
Assessment of Joint Pain (PtGAJP) and SF-36 summary
and domain scores. By evaluating changes across the 3
groups at week 24 and comparing scores to age-matched
and gender-
matched normative values (based on the
general population without chronic disease), we aimed
to examine improvements in PROs.
METHODS
Study design and patient population
SEAM-PsA was a 48-week, phase 3, multicentre, international RCT conducted at 124 hospitals/centres/clinics
in 17 countries (ClinicalTrials.gov, NCT02376790). Key
patient eligibility criteria included age ≥18 years old at
screening, active PsA (based on Classification Criteria
for Psoriatic Arthritis),19 naïve to etanercept and other
biologic agents, no prior use of MTX for PsA (prior treatment with MTX for psoriasis was allowed), ≥3 tender and
≥3 swollen joints (68/66 tender/swollen joint count) at
screening and baseline, and an active psoriatic skin lesion
≥2 cm in diameter. Patients were randomised 1:1:1 via
an interactive voice-response system to receive: (1) oral
MTX (target 20 mg/week) plus subcutaneous placebo
weekly, (2) etanercept 50 mg/week given subcutaneously
plus oral placebo weekly, or (3) etanercept at 50 mg/
week given subcutaneously plus oral MTX weekly (target
20 mg/week). Patients with an inadequate response at or
after week 24 (<20% improvement in tender and swollen
joint counts from baseline), received rescue therapy with
etanercept (50 mg/week) plus MTX (target 20 mg/week)
until week 48.
All PROs were evaluated at baseline and weeks 12, 24,
36 and 48. At each visit, PROs were completed before
administration of study medication and other study
procedures.
The SEAM-PsA trial was conducted in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from each patient, and each participating
site obtained protocol approval by an institutional
review board or independent ethics committee. Additional details about the design and eligibility criteria of
SEAM-PsA have been previously published.18 20
Outcomes
The primary endpoint of the SEAM-PsA trial was the
percentage of ACR20 responders at week 24, and the
key secondary endpoint was the percentage of patients
with MDA at week 24. These results have been previously
published.18
Additional study endpoints included the change in
PRO scores from baseline at week 24 in each treatment
group by HAQ-DI, PtGA, PtGAJP, SF-36 PCS, MCS and
eight individual domains: Physical Function, Role Physical, Bodily Pain, General Health, Vitality, Social Function,
Strand V, et al. RMD Open 2021;7:e001484. doi:10.1136/rmdopen-2020-001484
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Table 1 Demographics and baseline disease activity
Characteristics

Methotrexate
monotherapy n=284

Etanercept
monotherapy n=284

Methotrexate+ combination
therapy n=283

Age in years, mean (SD)

48.7 (13.1)

48.5 (13.5)

48.1 (12.7)

Female sex, n (%)

160 (56.3)

133 (46.8)

139 (49.1)

White race, n (%)

255 (89.8)

252 (88.7)

265 (93.6)

Duration of PsA in years, mean (SD)

3.6 (6.8)*

3.1 (6.0)†

3.0 (6.0)*

Median (Q1, Q3)

0.9 (0.1, 3.3)*

0.6 (0.1, 3.0)†

0.5 (0.1, 3.0)*

Prior use of non-biological DMARD, n (%)

38 (13.4)

26 (9.2)

43 (15.2)

Body mass index (kg/m ), mean (SD)

30.6 (7.1)

30.4 (6.6)‡

30.0 (6.7)

Swollen joint count (66 joints), mean (SD)

12.9 (9.9)

11.5 (9.6)‡

11.2 (9.1)§

Tender joint count (68 joints), mean (SD)

20.9 (15.0)

18.8 (14.5)]‡

20.0 (15.3)§

mTSS, mean (SE)

2.8 (0.1)¶

3.0 (0.1)**

2.7 (0.1)††

PASDAS, mean (SE)

6.1 (0.1)§

6.1 (0.1)‡‡

6.0 (0.1)§§

DAPSA, mean (SE)

46.5 (1.4)‡

43.4 (1.4)¶¶

43.8 (1.4)¶¶

>0 at baseline, n (%)

98 (34.5)

96 (33.8)

90 (31.8)

Mean (SE) for patients with >0 at baseline

164.9 (26.9)***

147.6 (20.8)†††

138.2 (23.9)‡‡‡

>0 at baseline, n (%)

191 (67.3)

189 (66.5)

196 (69.3)

Mean (SE) for patients with >0 at baseline

5.7 (0.3)§§§

5.5 (0.3)¶¶¶

5.9 (0.3)****

Psoriasis-affected BSA, mean % (SD)

12.7 (18.8)

10.8 (14.7)

10.7 (15.6)

sPGA, mean (SD)

2.6 (1.1)

2.6 (1.0)

2.5 (1.0)‡

HAQ-DI, mean (SE)

1.3 (0.04)‡

1.2 (0.04)

1.2 (0.04)§

Patient Global Assessment (0–100), mean (SE)

60.7 (1.3)‡

62.9 (1.3)

61.0 (1.2)§

Patient Global Assessment of Joint Pain (0–100), mean (SE)

56.1 (1.3)‡

56.5 (1.3)

55.7 (1.3)§

SF-36 PCS, mean (SE)

35.6 (0.5)§

37.8 (0.5)

37.4 (0.6)§

SF-36 MCS, mean (SE)

45.2 (0.7)§

45.1 (0.7)

46.3 (0.7)§

 Physical function

42.1 (1.5)§

48.5 (1.5)

49.0 (1.5)§

 Role physical

44.6 (1.5)§

48.5 (1.5)

50.2 (1.5)§

 Bodily pain

36.3 (1.1)§

39.8 (1.1)

39.3 (1.1)§

 General health

46.1 (1.1)§

48.1 (1.3)

47.1 (1.2)§

 Vitality

40.2 (1.2)§

43.1 (1.3)

42.0 (1.2)§

 Social function

58.3 (1.6)§

62.7 (1.6)

63.3 (1.6)§

 Role emotional

65.8 (1.7)§

65.4 (1.7)

70.0 (1.6)§

 Mental health

60.3 (1.3)§

60.8 (1.3)

62.5 (1.2)§

2

LDI

SPARCC Enthesitis Index

SF-36 domains, mean (SE)

*Number of patients analysed for mean values=231.
†Number of patients analysed for mean values=222.
‡Number of patients analysed for mean values=283.
§Number of patients analysed for mean values=282.
¶Number of patients analysed for mean values=269.
**Number of patients analysed for mean values=273.
††Number of patients analysed for mean values=274.
‡‡Number of patients analysed for mean values=279.
§§Number of patients analysed for mean values=280.
¶¶Number of patients analysed for mean values=281.
***Number of patients analysed for mean values=98.
†††Number of patients analysed for mean values=96.
‡‡‡Number of patients analysed for mean values=90.
§§§Number of patients analysed for mean values=191.
¶¶¶Number of patients analysed for mean values=189.
****Number of patients analysed for mean values=196.
BSA, body surface area; DAPSA, Disease Activity Index for Psoriatic Arthritis; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment
Questionnaire-Disability Index; LDI, Leeds Dactylitis Index; MCS, Mental Component Summary; mTSS, van der Heijde modified Total Sharp Score; PASDAS,
Psoriatic Arthritis Disease Activity Score; PCS, Physical Component Summary; PsA, psoriatic arthritis; Q1, first quartile; Q3, third quartile; SE, standard error;
SF-36, Medical Outcomes Study Short Form-36 Questionnaire; SPARCC, Spondyloarthritis Research Consortium of Canada; sPGA, static Physician Global
Assessment.
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Table 2 Change in patient-reported outcome scores from baseline at week 24
Patient-reported outcome: least square
mean change from baseline at week 24
HAQ-DI*

Methotrexate
monotherapy n=284
–0.39

Etanercept
monotherapy n=284
–0.41

Methotrexate+etanercept
combination therapy n=283
–0.44

PtGA*

–22.70

–31.64†

–29.04‡

PtGAJP*

–18.95

–24.12‡

–24.90‡

SF-36 PCS§

5.68

7.38‡

7.62‡

SF-36 MCS§

3.48

2.99

3.46

 Physical function

14.47

17.42

17.54

 Role physical

13.81

16.28

17.66

 Bodily pain

16.03

20.47‡

21.66¶

7.77

11.93¶

10.9

 Vitality

10.46

10.99

13.94‡

 Social function

14.58

11.37

13.22

 Role emotional
 Mental health

8.58
6.92

9.76
7.5

8.08
8.91

SF-36 domain scores§

 General health

*For HAQ-DI, PtGA and PtGAJP, a lower score indicates a more positive health state, so greater negative changes from baseline indicate
improvement.
†P value for comparison with methotrexate monotherapy was ≤0.001.
‡P value for comparison with methotrexate monotherapy was ≤0.05.
§For SF-36, a higher score indicates a more positive health state, so greater positive changes from baseline indicate improvement.
¶P value for comparison with methotrexate monotherapy was ≤0.01.
HAQ-DI, Health Assessment Questionnaire-Disability Index; MCS, Mental Component Summary; PCS, Physical Component Summary;
PtGA, Patient Global Assessment; PtGAJP, Patient Global Assessment of Joint Pain; SF-36, Medical Outcomes Study Short Form-36
Questionnaire.

Role Emotional, and Mental Health. Exploratory analyses
examined the proportion of patients in each treatment
group who reported improvements from baseline at week
24≥minimal clinically important differences (MCID;
which is the degree of change that is perceptible and clinically meaningful to patients21) in HAQ-DI, PtGA, PtGAJP
and SF-36 PCS, MCS and the domains.22–25 We also
examined the proportion of patients in each treatment
group who reported scores at week 24≥age-matched and
gender-matched normative values in HAQ-DI and SF-36
PCS, MCS and domain scores.26 There are no normative
values defined for PtGA and PtGAJP.
Statistical analyses
SEAM-PsA was not powered to detect differences between
PROs. As such, p values for efficacy endpoints other
than the primary and key secondary endpoints were
not adjusted for multiplicity and should be considered
descriptive. All treatment comparisons were performed
using the Cochran-Mantel-Haenszel test with prior use of
non-biological DMARDS (non-bDMARDS) and a baseline body mass index (BMI) status (≤30 kg/m2 or >30 kg/
m2) as stratification factors. An analysis of covariance
(ANCOVA) model that adjusted for baseline BMI status
and prior non-bDMARD use compared the treatment
differences between the MTX monotherapy group versus
the two etanercept-
containing groups for changes in
4

PRO scores at week 24 from baseline. Statistical analyses
were performed using SAS V.9.4 (SAS Institute).
RESULTS
Patient characteristics
A total of 851 patients completed the study. Baseline
demographic and disease characteristics were well
balanced across the three treatment groups (table 1).
Most patients were Caucasian (90.7%), and mean (SD)
age was 48.4 (13.1) years. Most patients were early in the
course of their disease, with the mean (SD) duration of
PsA of 3.2 (6.3) years (median 0.6 years). Prior MTX
for the treatment of psoriasis was received by 4.9% of
patients. From weeks 4 to 24, patients in the MTX groups
continued a mean MTX dose that was >18.8 mg (median
20 mg).
Change in PRO scores
An examination of changes in PRO scores from baseline to week 24 indicated that improvements generally
occurred across all three treatment groups. For most
SF-36 domains, changes from baseline at week 24 were
numerically higher in the etanercept groups compared
with MTX monotherapy (table 2).
Treatment differences between MTX monotherapy
versus the two etanercept groups by changes in PRO
scores at week 24 after adjusting for baseline BMI status
Strand V, et al. RMD Open 2021;7:e001484. doi:10.1136/rmdopen-2020-001484
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Figure 1 Spydergram of domain scores from baseline
to week 24 versus age-matched and gender-matched
normative scores. The spydergram was generated using
domain raw scores (range: 0–100); age-gender norms in
the USA were matched to the study population. The age-
matched and gender-matched normative values for the
SF-36 domains were: 82.01 for PF, 82.55 for RP, 72.86 for
BP, 70.31 for GH, 58.89 for VT, 85.11 for SF, 88.12 for RE
and 75.94 for MH. Missing values were not imputed. A
higher SF-36 score indicates a more positive health state,
so greater positive changes from baseline. P values in red
indicate p≤0.05; p values in blue indicate p≤0.01. A, age; BL,
baseline; BP, Bodily Pain; ETN, etanercept; G, gender; GH,
General Health; MH, Mental Health; MTX, methotrexate; PF,
Physical Function; RE, Role Emotional; RP, Role Physical; SF,
Social Function; VT, Vitality; Wk, week.

and prior non-
bDMARD use are shown in table 2.
Patients receiving etanercept monotherapy reported
greater improvements from baseline in PtGA (p<0.001),
PtGAJP (p=0.032), SF-36 PCS (p=0.033) and the domains
of Bodily Pain (p=0.034) and General Health (p=0.01)
compared with MTX monotherapy. Patients receiving
combination therapy reported greater improvements
from baseline in PtGA (p=0.012), PtGAJP (p=0.014),
SF-36 PCS (p=0.015), Bodily Pain (p=0.007), and Vitality
(p=0.05) domains compared with MTX monotherapy.
We generated a spydergram (figure 1) to illustrate how
mean baseline and week 24 SF-36 domain scores across
treatment groups compared against USA age-matched
and gender-matched normative scores matched to the
protocol population.27 Published normative values are:
HAQ-DI: ≤0.25, SF-36 PCS and MCS: ≥50, and domain
scores listed in the figure legend, with missing values not
imputed. Figure 1 illustrates how the largest differences
between MTX monotherapy and etanercept treatment
groups were reported in Bodily Pain, General Health,
and Vitality Domains.
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Threshold analyses
Patients reporting improvements in PRO scores at week 24 ≥
MCID
We examined the percentage of patients in each treatment group who reported changes in PRO scores at week
24≥MCID in HAQ-
DI, PtGA, PtGAJP and SF-36 PCS,
MCS and domains. The etanercept monotherapy and
combination therapy groups generally included a higher
percentage of patients reporting clinically meaningful
changes in PRO scores at week 24 (figure 2) compared
with MTX monotherapy. The highest percentages of clinically meaningful improvements were reported in PtGA
(66.7% with MTX monotherapy vs 78.3% with etanercept
monotherapy, and 75.1% with combination therapy).
Analyses comparing across treatment groups generally
showed similar proportions of patients reporting changes≥MCID at week 24. Exceptions were higher percentages
in both etanercept groups in PtGA (66.7% with MTX
monotherapy vs 78.3% with etanercept monotherapy;
p=0.005) and PtGAJP (65.1% with MTX monotherapy vs
73.9% with combination therapy; p=0.038; figure 2).
Patients reporting PRO scores ≥ age-matched and gendermatched normative values at week 24
Across PROs, the percentages of patients reporting
scores at week 24≥normative values ranged from 20.8%
(General Health domain) to 51.0% (SF-36 MCS) with
MTX monotherapy, 30.9% (Role Physical domain) to
48.8% (SF-36 MCS) with etanercept monotherapy, and
30.6% (General Health domain) to 52.3% (SF-36 MCS)
with combination therapy (figure 3). Higher percentages
of patients in both etanercept groups reported scores at
week 24≥normative values (p≤0.05) in HAQ-DI, SF-36
PCS, and Role Physical, Bodily Pain, and General Health
domains. Numerically, more patients receiving combination therapy reported scores at week 24≥normative values
in Vitality and Mental Health domains compared with
MTX monotherapy (p≤0.05; figure 3).
DISCUSSION
Our analyses of the PRO data collected from the
SEAM-
PsA RCT indicate that patients receiving MTX
monotherapy, etanercept monotherapy and MTX plus
etanercept all reported improvements in PRO scores
at week 24 compared with baseline. Both the etanercept monotherapy and MTX plus etanercept groups
reported greater improvements from baseline compared
with MTX in PtGA, PtGAJP, SF-36 PCS and Bodily Pain
domain. Additionally, the etanercept monotherapy
group reported greater improvement in General Health
and the combination therapy group greater improvement in Vitality compared with MTX monotherapy.
Improvements in PROs reported with etanercept monotherapy and MTX plus etanercept were numerically
similar, although this was not statistically evaluated as the
trial was not powered for statistical comparison between
these two groups.
5
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Figure 2 Percentages of patients reporting PRO improvements≥MCID week 24. *P values are descriptive and are for
comparison with methotrexate monotherapy. Only p values ≤0.05 are shown. MCID values were change from baseline ≤
–0.35 for HAQ-DI, ≤ –10.0 for PtGA, ≤ –10.0 for PtGAJP, ≥2.5 for SF-36 PCS, ≥2.5 for SF-36 MCS, and ≥5.0 for each SF-36
domain. BP, Bodily Pain; GH, General Health; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCID, minimal
clinically important difference; MCS, Mental Component Summary; MH, Mental Health; PCS, Physical Component Summary;
PF, Physical Function; PRO, patient-reported outcome; PtGA, Patient Global Assessment; PtGAJP, Patient Global Assessment
of Joint Pain; RE, Role Emotional; RP, Role Physical; SF, Social Function; SF-36, Medical Outcomes Study Short Form-36
Questionnaire; VT, vitality.

Reported results indicated that treating patients with
PsA with etanercept either monotherapy or in combination with MTX results in greater, more clinically meaningful improvements in PROs compared with MTX
monotherapy. Results from the primary and secondary
endpoints of SEAM-PsA, for which the RCT analyses were

powered, indicate that etanercept monotherapy and
combination therapy were statistically significantly more
effective than MTX monotherapy by ACR20 responses
and MDA at week 24.18 PRO results from these analyses
most closely aligned with ACR responses and MDA at
week 24 are those examining changes from baseline at

Figure 3 Percentages of patients reporting PRO scores ≥normative values at week 24. *P values are descriptive and are for
comparison with methotrexate monotherapy at week 24. Only P values ≤0.05 are shown. Normative values were ≤0.25 for
HAQ-DI; ≥50 for SF-36 PCS, and ≥50 for SF-36 MCS. Age/gender normalised values for the SF-36 domains were 82.01 for
PF, 82.55 for RP, 72.86 for BP, 70.31 for GH, 58.89 for VT, 85.11 for SF, 88.12 for RE, and 75.94 for MH. BP, Bodily Pain, GH,
General Health; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCS, Mental Component Summary; MH, Mental
Health; PCS, Physical Component Summary; PF, Physical Function; PRO, patient-reported outcome; RE, Role Emotional; RP,
Role Physical; SF, Social Function; SF-36, Medical Outcomes Study Short Form-36 Questionnaire; VT, Vitality.
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week 24 in PtGA, PtGAJP, SF-36 PCS, and General Health
domain. These PROs may be most sensitive for capturing
how patients with PsA experience their disease.
The internal validity of our study’s results is strengthened due to SEAM-PsA being an active-comparator RCT
that directly compared PROs in patients treated with
MTX, etanercept and combination therapy. In addition,
the active comparator included patients receiving MTX
at currently recommended doses (~20 mg/week).28
Results from our study are different from those
observed in a phase 3 trial of golimumab in combination
with MTX versus MTX monotherapy,17 in which golimumab did not show significant improvements in physical
PCS at week 22 (SF-36 PCS score of 50.1 vs 50.7; p=0.543).
In our study, etanercept monotherapy or in combination with MTX showed significant improvements in PCS
scores at week 24 vs MTX monotherapy (least squares
mean change from baseline in SF-36 PCS score of 7.38
and 7.62, respectively, vs 5.68; p≤0.05) for both comparisons. However, similar to observations in our study, the
golimumab trial did not find any significant improvements in MCS scores.17
This study has a few limitations. There was no placebo
group in the trial. This is important because including a
placebo arm could help contextualise the results of this
trial with prior RCTs in PsA. It is well known that active
comparator trials, without placebo, result in higher
responses as all patients have higher ‘expectation bias’,
knowing that they are all receiving active treatment.29 30
However, there are ethical issues regarding prolonged
placebo exposure in patients with active, especially early
disease. Another limitation is that the SEAM-PsA trial
was not powered to detect differences between etanercept groups and thus they could not be compared. The
most important limitation was the generalisability of our
results, as the treatment-naïve population enrolled in this
RCT may not reflect the experiences of typical patients
with severe or moderate PsA. However, our results are
likely most relevant to patients with relatively early, active
PsA disease.
Future research in PsA should include active comparators and PROs in their design. In addition, direct comparisons between different treatments could help determine
which treatments are more effective in patients with PsA.
Considering results from this RCT, PROs should be incorporated in discussions between patients and clinicians
regarding their choice of treatment, to incorporate the
patient’s perspective. Improvements in PROs reported
with etanercept may inform decision-
making between
clinicians and patients with PsA.
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